Prudential Financial’s LogicBio Therapeutics LOGC Stock Holding History
Bought
Maintained
Sold
Prudential Financial's LOGC Position: Q4 2022 in Review
Prudential Financial sold out of LogicBio Therapeutics (LOGC) in Q4 2022, closing a stake of 98,600 shares — an estimated $27K sold.
Prudential Financial first reported a position in LOGC in Q2 2022 and held it in 2 quarters. The position peaked at $27K in Q3 2022. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Prudential Financial reported no remaining LogicBio Therapeutics position as of Q4 2022 after selling out during the quarter.
- Prudential Financial sold 98,600 LogicBio Therapeutics shares in Q4 2022, an estimated $27K.
- Prudential Financial first reported a position in LogicBio Therapeutics in Q2 2022 and held it in 2 quarters.
- Prudential Financial's LogicBio Therapeutics position peaked at $27K in Q3 2022.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics as of Q4 2022.
Based on Prudential Financial's 13F filing for Q4 2022, filed 14 Feb 2023.